GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
GLP-1 Crackdown: What the FDA Really Means & Why Compounding Still Matters
-
Lu par :
-
De :
There’s been a lot of noise lately around semaglutide, tirzepatide, and other GLP-1 medications—especially as the FDA cracks down on certain compounded versions. But what’s really going on? And what should patients and providers know?
In this solo episode, I unpack the truth behind the headlines. We’ll clarify what GLP-1 medications actually are (hint: they’re not insulin), why they’re in such high demand, and how compounding pharmacies legally stepped in during national shortages. I’ll also break down the difference between 503A and 503B pharmacies and share how to spot quality in compounded meds.
Whether you’re a patient, provider, or pharmacy pro, this episode clears the fog around GLP-1s and gives you real tools to stay informed.
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment
